Genmab — April 2020
-
Ritzau: Sanofi skriver i regnskabet, at omkring halvdelen af væksten i første kvartal skyldes virusudbruddet, der har medvirket til, at distributionsled og patienter har opbygget ekstra forråd af medicin. - Kan måske få betydning for forbigående flotte salgstal for dara?
-
Well, Winkel has ruled out home infusion. He says it has to take place in a clinic. But with sc after the first couple of infusions when observation is no longer needed, it could be a possibility. I don't know if they have home-nurses in US like we have it in DK.
-
Johnson & Johnson finder produktionspartner til mulig coronavaccine
Amerikansk kontraktproducent skal i første omgang producere en mulig coronavaccine fra Johnson & Johnson.
(medwatch.dk)
-
Så har AlphaValue iflg. Bloomberg 23.04.2020 ændret sin anbefaling til reduce og ny målkurs på 1687.
-
-
Ocrevus is the only approved treatment for primary progressive MS with off-label use also reported in secondary progressive disease. In the short term, KOLs anticipate Novartis’ ofatumumab posing the most significant competitive threat to Roche’s drug, citing its subcutaneous formulation and faster B-cell repletion as significant advantages. Approval of ofatumumab is expected later this year.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind